LONDON (Alliance News) - Motif Bio PLC said Monday that an independent report from JMI Laboratories showed "encouraging" results for its flagship antibiotic iclaprim against a range of Gram-positive bacteria including staphylococcus aureus.
Staphylococcus aureus is one of the key causes of acute bacterial skin and skin structure infection, and hospital-acquired bacterial pneumonia.
"We believe that iclaprim will prove to be an important option for treating these life-threatening infections where currently available treatments are not fully effective due to resistance or side effects," said Chief Medical Officer David Huang in a statement.
The report was of a study of iclaprim against more than 2,000 bacterial strains, and found that iclaprim was 16 times more potent than trimethoprim, an antibacterial dihydrofolate reductase inhibitor.
Shares in Motif Bio were down 0.4% at 51.80 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
